This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BIIB vs. MYGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BIIB vs. MYGN: Which Stock Is the Better Value Option?
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
Are Investors Undervaluing Biogen (BIIB) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
by Zacks Equity Research
BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
by Zacks Equity Research
Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Sage Therapeutics' third-quarter 2024 earnings miss estimates. Stock falls in after-hours trading.
Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen (BIIB) delivered earnings and revenue surprises of 8.22% and 0.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On CDXC's third-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its marketed product Niagen and updates on the pipeline.
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Zoetis Gears Up to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in third-quarter 2024 in both the United States and International segments.
Regeneron to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
Seeking Clues to Biogen (BIIB) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Biogen (BIIB) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Ecolab's Set to Report Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
ECL third-quarter results are likely to reflect continued segmental strength.
Cardinal Health to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Despite recent supply chain challenges, new facilities and the acquisition of Specialty Networks are likely to have driven CAH's growth
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will New Drugs Help Biogen Surpass Q3 Earnings Estimates?
by Zacks Equity Research
In the third quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen
by Zacks Equity Research
Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen are included in this Analyst Blog.
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.